Erythromycin for prokinesis: Imprudent prescribing?

Critical Care

Volumn 10, Issue 1, 2005, Pages

  Dall'Antonia, Martino ^a   Wilks, Mark ^b   Coen, Pietro G ^c   Bragman, Susan ^a   Millar, Michael R ^d  

^a NATIONAL HEALTH SERVICE   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; MACROLIDE; METOCLOPRAMIDE; PROKINETIC AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; CLOSTRIDIUM DIFFICILE; CRITICALLY ILL PATIENT; DRUG EXPOSURE; DRUG USE; ENTERIC FEEDING; GASTROINTESTINAL MOTILITY DISORDER; GRAM NEGATIVE BACTERIUM; HIGH RISK PATIENT; HUMAN; INFECTION CONTROL; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; INTESTINE BLOOD FLOW; INTESTINE FUNCTION; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NOTE; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SEPSIS; SLOW DRUG RELEASE; STAPHYLOCOCCUS INFECTION; STOMACH SUCTION; SURVIVAL RATE; VENTILATOR ASSOCIATED PNEUMONIA; WOUND HEALING;

EID: 34447579278     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc3956     Document Type: Note

References (14)

1. Livermore DM Minimising antibiotic resistance Lancet Infect Dis 2005 5 450-459 10.1016/S1473-3099(05)70166-3 15978531
2. House of Lords Select Committee on Science and Technology Seventh Report http://www.publications.parliament.uk/pa/ld199798/ldselect/ldsctech/ 081vii/st0701.htm
3. Lipsitch M Samore MH Antimicrobial use and antimicrobial resistance: A population perspective Emerg Infect Dis 2002 8 347-354 11971765
4. Dall'Antonia M Coen PG Wilks M Whiley A Millar M Competition between methicillin-sensitive and-resistant Staphylococcus aureus in the anterior nares J Hosp Infect 2005 61 62-67 10.1016/j.jhin.2005.01.008 15893854
5. Berg HF Tjhie JH Scheffer GJ Peeters MF van Keulen PH Kluyt-mans JA Stobberingh EE Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of S. aureus after therapy with slow-release clarithromicin: A randomized, double-blind, placebo-controlled study Antimicrob Agents Chemother 2004 48 4138-4188 10.1128/AAC.48.11.4183-4188.2004
6. Carsenti-Dellamonica H Galimand M Vandenbos F Pradier C Roger PM Dunais B Sabah M Mancini G Dellamonica P In vitro selection of mutants of Streptococcus pneumoniae resistant to macrolides and linezolid: relationship with susceptibility to penicillin G or macrolides J Antimicrob Chemother 2005 56 633-642 10.1093/jac/dki301 16135525
7. Warny M Pepin J Fang A Killgore G Thompson A Brazier J Frost E McDonald LC Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe Lancet 2005 366 1079-1084 10.1016/S0140-6736(05)67420-X 16182895
8. John R Brazier JS Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK J Hosp Infect 2005 61 11-14 10.1016/j.jhin.2005.01.020 16002183
9. Mullany P Wilks M Tabaqchali S Transfer of macrolide-lin-cosamide-streptogramin B (MLS) resistance in Clostridium difficile is linked to a gene homologous with toxin A and is mediated by a conjugative transposon, Tn5398 J Antimicrob Chemother 1995 35 305-315 7759394
10. Doherty WL Winter B Prokinetic agents in critical care Crit Care 2003 7 206-208 270665 12793865 10.1186/cc1849
11. Canadian Critical Care Society Clinical Practice Guidelines for Nutritional Support in Mechanically Ventilated, Adult Critically Ill Patients. Toronto 2003
12. Booth CM Heyland DK Paterson WG Gastrointestinal promotility drugs in the critical care setting: A systematic review of the evidence Crit Care Med 2002 30 1653-1654 12130996
13. Talle NJ Tack J Peeters T What comes after macrolides and other motility stimulants? Gut 2001 49 317-318 11511547
14. Department of Health Winning Ways: Report from the Chief Medical Officer. London 2003